FES

Tyrosine-protein kinase Fes/Fps

48,368 patent compounds predicted against FES, 39,890 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sunitinib (SCHEMBL8081)	1.00	2/20
Sunitinib (SCHEMBL8082)	1.00	2/20
Linifanib (SCHEMBL93804)	1.00	2/20
Crizotinib (SCHEMBL93829)	1.00	2/20
Crizotinib (SCHEMBL94020)	1.00	2/20
Tae-684 (SCHEMBL282775)	1.00	2/20
Sunitinib (SCHEMBL18648)	0.92	2/20
Sunitinib (SCHEMBL55459)	0.84	2/20
SCHEMBL232936	0.79	2/20
SCHEMBL143584	0.78	2/20
SCHEMBL143543	0.77	2/20
SCHEMBL143185	0.75	2/20
SCHEMBL144887	0.74	2/20
SCHEMBL144383	0.74	2/20
SCHEMBL139873	0.72	2/20
SCHEMBL143316	0.71	2/20
SCHEMBL144905	0.71	2/20
SCHEMBL145888	0.71	2/20
SCHEMBL142711	0.70	2/20
SCHEMBL72322	0.69	2/20

Germline variants in FES on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full FES gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to FES by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer	PHASE4	RECRUITING
[18F]FES PET/CT in Endocrine Refractory Breast Cancer	PHASE2	COMPLETED
[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer	PHASE2	RECRUITING
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy	PHASE2	ACTIVE_NOT_RECRUITING
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients	PHASE2	ENROLLING_BY_INVITATION
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	PHASE1/PHASE2	RECRUITING
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer	PHASE2	COMPLETED
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy	PHASE2	ACTIVE_NOT_RECRUITING
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)	PHASE2	COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites	PHASE2	COMPLETED
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer	PHASE2	COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency	PHASE1	RECRUITING
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...	PHASE1	RECRUITING
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer	nan	COMPLETED
Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer	nan	UNKNOWN
MPN Childhood Registry	nan	RECRUITING
The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer	nan	UNKNOWN
Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer	nan	ACTIVE_NOT_RECRUITING
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells	nan	COMPLETED
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Pulsed Electro Magnetic Fields (PEMF) in Depression	nan	COMPLETED
Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.	nan	COMPLETED
Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FES binder may also engage these)

Protein	Name	Similarity
P16879	—	1.000	P16879 →
P14238	—	1.000	P14238 →
P00542	—	1.000	P00542 →
P00530	—	0.997	P00530 →
P00541	—	0.986	P00541 →
A1IGU3	—	0.981	A1IGU3 →
Q99JB8	—	0.981	Q99JB8 →
P70218	—	0.980	P70218 →
A1IGU4	—	0.980	A1IGU4 →
A1IGU5	—	0.980	A1IGU5 →
Q6ZT62	—	0.978	Q6ZT62 →
Q15027	—	0.978	Q15027 →
Q8C2K1	—	0.978	Q8C2K1 →
Q8CJ53	—	0.978	Q8CJ53 →
O15068	—	0.978	O15068 →
GRB7	Growth factor receptor-bound protein 7	0.978	landscape →
Q99KF0	—	0.976	Q99KF0 →
CDC42BPG	Serine/threonine-protein kinase MRCK gamma	0.976	landscape →
Q8K045	—	0.976	Q8K045 →
Q64096	—	0.976	Q64096 →
Q9BXL6	—	0.975	Q9BXL6 →
Q5RCJ1	—	0.975	Q5RCJ1 →
Q63406	—	0.975	Q63406 →
Q8K2H4	—	0.975	Q8K2H4 →
Q8R5F8	—	0.975	Q8R5F8 →
Q9UKS6	—	0.975	Q9UKS6 →
Q03160	—	0.974	Q03160 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.974	landscape →
P55146	—	0.974	P55146 →
O94887	—	0.974	O94887 →